Targets for the design of antiviral agents:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Tagungsbericht Buch |
| Sprache: | English |
| Veröffentlicht: |
New York [u.a.]
Plenum Pr.
1984
|
| Schriftenreihe: | [NATO ASI series
Series A, Life sciences] ; 73 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII, 378 S. |
| ISBN: | 0306416182 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV000172283 | ||
| 003 | DE-604 | ||
| 005 | 20190312 | ||
| 007 | t | ||
| 008 | 870612s1984 |||| 10||| eng d | ||
| 020 | |a 0306416182 |9 0-306-41618-2 | ||
| 035 | |a (OCoLC)476662748 | ||
| 035 | |a (DE-599)BVBBV000172283 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-355 |a DE-188 | ||
| 050 | 0 | |a RM411 | |
| 082 | 0 | |a 615.37 |2 19 | |
| 084 | |a XI 3105 |0 (DE-625)152993:12911 |2 rvk | ||
| 245 | 1 | 0 | |a Targets for the design of antiviral agents |c ed. by E. De Clercq ... |
| 264 | 1 | |a New York [u.a.] |b Plenum Pr. |c 1984 | |
| 300 | |a XII, 378 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a [NATO ASI series : Series A, Life sciences] |v 73 | |
| 650 | 4 | |a Antiviral agents | |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Viruskrankheit |0 (DE-588)4063605-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Viruzid |0 (DE-588)4139555-4 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1983 |z Les Arcs |2 gnd-content | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1983 |z Lestres |2 gnd-content | |
| 689 | 0 | 0 | |a Viruskrankheit |0 (DE-588)4063605-7 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Viruzid |0 (DE-588)4139555-4 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a De Clercq, Erik |4 edt | |
| 711 | 2 | |a Advanced Study Institute on Targets for the Design of Antiviral Agents |d 1983 |c Les Arcs |j Sonstige |0 (DE-588)801724-4 |4 oth | |
| 830 | 0 | |a [NATO ASI series |v Series A, Life sciences] ; 73 |w (DE-604)BV000902941 |9 73 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000098325&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-000098325 | ||
Datensatz im Suchindex
| _version_ | 1804114631811137536 |
|---|---|
| adam_text | TARGETS FOR THE DESIGN OF ANTIVIRAL AGENTS EDITED BY CLERCQ REGA
INSTITUTE FOR MEDICAL RESEARCH CATHOLIC UNIVERSITY OF LEUVEN LEUVEN,
BELGIUM R.T.WALKER THE UNIVERSITY OF BIRMINGHAM BIRMINGHAM, UNITED
KINGDOM UNIVERSITATS- BIBLIOTHEK PLENUM PRESS NEW YORK AND LONDON
PUBLISHED IN COOPERATION WITH NATO SCIENTIFIC AFFAIRS DIVISION CONTENTS
INTRODUCTION OVERVIEW OF THE POSSIBLE TARGETS FOR VIRAL CHEMOTHERAPY 1
W.H. PRUSOFF, T.-S. LIN, W.R. MANCHINI, M.J, OTTO, S.A. SIEGEL, AND J.J.
LEE VIRAL TARGETS HERPESVIRUS TARGET CONSIDERATIONS FOR THE DESIGN OF
ANTIVIRAL AGENTS , 29 F. RAPP AND B. WIGDAHL PICORNAVIRUSES AND
TOGAVIRUSES: TARGET FOR DESIGN OF ANTIVIRALS 6L B.D. KORANT, K.
LONBERG-HOLM, AND P. LACOLLA TARGETS IN NEGATIVE STRAND RNA VIRUSES
(EXCLUDING ORTHO- * AND PARAMYXOVIRUSES . . 99 D.H.L. BISHOP TARGETS
FOR THE DESIGN OF ANTIVIRAL AGENTS: TARGETS IN ORTHOMYXOVIRUSES 121 J.J.
SKEHEL, AND D.C. WILEY BIOLOGIC AND CHEMATHERAPEUTIC FORAYS INTO THE
FIELD OF UNCONVENTIONAL VIRUSES 131 P. BROWN ANTIVIRAL COMPOUNDS ANTI
INFLUENZA VIRUS ACTIVITY OF AMANTADINE, RIMANTADINE AND ANALOGUES 159
J.S. OXFORD XII CONTENTS ANTIVIRAL ACTION OF
2-(A-HYDROXYBENZYL)- BENZI:MIDAZOLE (HBB) 177 H.J. EGGERS ANTIRHINOVIRUS
DRUGS I89 D.A.J. TYRRELL PYRIMIDINE NUCLEOSIDE ANALOGUES AS ANTIVIRAL
AGENTS 203 E. DE CLERCQ. PURINE NUCLEOSIDE ANALOGS AS ANTIVIRAL AGENTS
231 J.C. DRACH STRATEGIES IN THE DESIGN OF OLIGONUCLEOTIDES AS POTENTIAL
ANTIVIRAL AGENTS 259 P.F. TORRENCE, J. IMAI, K. LESIAK, J.-C. JAMOULLE,
H. SAWAI, J. WARINNIER, J. BALZARINI, AND E. DE CLERCQ. OLIGOPEPTIDES AS
SPECIFIC ANTIVIRAL AGENTS 287 P.W. CHOPPIN, CD. RICHARDSON, AND A,
SCHEID VIRUS ASSOCIATED DNA POLYMERIZING ACTIVITIES: THEIR ROLE IN
DESIGNING ANTIVIRAL AND ANTITUMOR AGENTS . . . . 307 P. CHANDRA, I.
DERAIRHAN, U. EBENER, AND B, KORNHUBER CONCLUSION ANTIVIRAL AGENTS: WHY
NOT A PENICILLIN FOR VIRAL INFECTIONS? 337 G..J. GALASSO PARTICIPANTS
363 INDEX 367
|
| any_adam_object | 1 |
| author2 | De Clercq, Erik |
| author2_role | edt |
| author2_variant | c e d ce ced |
| author_facet | De Clercq, Erik |
| building | Verbundindex |
| bvnumber | BV000172283 |
| callnumber-first | R - Medicine |
| callnumber-label | RM411 |
| callnumber-raw | RM411 |
| callnumber-search | RM411 |
| callnumber-sort | RM 3411 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 3105 |
| ctrlnum | (OCoLC)476662748 (DE-599)BVBBV000172283 |
| dewey-full | 615.37 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.37 |
| dewey-search | 615.37 |
| dewey-sort | 3615.37 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01936nam a2200469 cb4500</leader><controlfield tag="001">BV000172283</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190312 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1984 |||| 10||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0306416182</subfield><subfield code="9">0-306-41618-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)476662748</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000172283</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM411</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.37</subfield><subfield code="2">19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3105</subfield><subfield code="0">(DE-625)152993:12911</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targets for the design of antiviral agents</subfield><subfield code="c">ed. by E. De Clercq ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York [u.a.]</subfield><subfield code="b">Plenum Pr.</subfield><subfield code="c">1984</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 378 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">[NATO ASI series : Series A, Life sciences]</subfield><subfield code="v">73</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral agents</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Viruskrankheit</subfield><subfield code="0">(DE-588)4063605-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Viruzid</subfield><subfield code="0">(DE-588)4139555-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1983</subfield><subfield code="z">Les Arcs</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1983</subfield><subfield code="z">Lestres</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Viruskrankheit</subfield><subfield code="0">(DE-588)4063605-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Viruzid</subfield><subfield code="0">(DE-588)4139555-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Clercq, Erik</subfield><subfield code="4">edt</subfield></datafield><datafield tag="711" ind1="2" ind2=" "><subfield code="a">Advanced Study Institute on Targets for the Design of Antiviral Agents</subfield><subfield code="d">1983</subfield><subfield code="c">Les Arcs</subfield><subfield code="j">Sonstige</subfield><subfield code="0">(DE-588)801724-4</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">[NATO ASI series</subfield><subfield code="v">Series A, Life sciences] ; 73</subfield><subfield code="w">(DE-604)BV000902941</subfield><subfield code="9">73</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000098325&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000098325</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1983 Les Arcs gnd-content (DE-588)1071861417 Konferenzschrift 1983 Lestres gnd-content |
| genre_facet | Konferenzschrift 1983 Les Arcs Konferenzschrift 1983 Lestres |
| id | DE-604.BV000172283 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T15:09:48Z |
| institution | BVB |
| institution_GND | (DE-588)801724-4 |
| isbn | 0306416182 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-000098325 |
| oclc_num | 476662748 |
| open_access_boolean | |
| owner | DE-12 DE-355 DE-BY-UBR DE-188 |
| owner_facet | DE-12 DE-355 DE-BY-UBR DE-188 |
| physical | XII, 378 S. |
| publishDate | 1984 |
| publishDateSearch | 1984 |
| publishDateSort | 1984 |
| publisher | Plenum Pr. |
| record_format | marc |
| series | [NATO ASI series |
| series2 | [NATO ASI series : Series A, Life sciences] |
| spelling | Targets for the design of antiviral agents ed. by E. De Clercq ... New York [u.a.] Plenum Pr. 1984 XII, 378 S. txt rdacontent n rdamedia nc rdacarrier [NATO ASI series : Series A, Life sciences] 73 Antiviral agents Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Viruskrankheit (DE-588)4063605-7 gnd rswk-swf Viruzid (DE-588)4139555-4 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1983 Les Arcs gnd-content (DE-588)1071861417 Konferenzschrift 1983 Lestres gnd-content Viruskrankheit (DE-588)4063605-7 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Viruzid (DE-588)4139555-4 s De Clercq, Erik edt Advanced Study Institute on Targets for the Design of Antiviral Agents 1983 Les Arcs Sonstige (DE-588)801724-4 oth [NATO ASI series Series A, Life sciences] ; 73 (DE-604)BV000902941 73 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000098325&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Targets for the design of antiviral agents [NATO ASI series Antiviral agents Pharmakotherapie (DE-588)4076066-2 gnd Viruskrankheit (DE-588)4063605-7 gnd Viruzid (DE-588)4139555-4 gnd |
| subject_GND | (DE-588)4076066-2 (DE-588)4063605-7 (DE-588)4139555-4 (DE-588)1071861417 |
| title | Targets for the design of antiviral agents |
| title_auth | Targets for the design of antiviral agents |
| title_exact_search | Targets for the design of antiviral agents |
| title_full | Targets for the design of antiviral agents ed. by E. De Clercq ... |
| title_fullStr | Targets for the design of antiviral agents ed. by E. De Clercq ... |
| title_full_unstemmed | Targets for the design of antiviral agents ed. by E. De Clercq ... |
| title_short | Targets for the design of antiviral agents |
| title_sort | targets for the design of antiviral agents |
| topic | Antiviral agents Pharmakotherapie (DE-588)4076066-2 gnd Viruskrankheit (DE-588)4063605-7 gnd Viruzid (DE-588)4139555-4 gnd |
| topic_facet | Antiviral agents Pharmakotherapie Viruskrankheit Viruzid Konferenzschrift 1983 Les Arcs Konferenzschrift 1983 Lestres |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=000098325&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000902941 |
| work_keys_str_mv | AT declercqerik targetsforthedesignofantiviralagents AT advancedstudyinstituteontargetsforthedesignofantiviralagentslesarcs targetsforthedesignofantiviralagents |